Dundas Partners’s Bristol-Myers Squibb BMY Stock Holding History

Dundas Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-180,191	Closed	-$10.7M	–	56
2021 Q3	$10.7M	Hold	180,191	–	–	1.5%	33
2021 Q2	$12M	Buy	180,191 +9,696	+6%	+$632K	1.75%	33
2021 Q1	$10.8M	Hold	170,495	–	–	1.71%	33
2020 Q4	$12.1M	Buy	170,495 +13,293	+8%	+$817K	1.77%	31
2020 Q3	$9.48M	Hold	157,202	–	–	1.9%	29
2020 Q2	$9.24M	Hold	157,202	–	–	2.02%	29
2020 Q1	$8.78M	Buy	157,202 +6,249	+4%	+$382K	2.3%	24
2019 Q4	$9.68M	Buy	150,953 +3,660	+2%	+$210K	2.19%	26
2019 Q3	$7.47M	Hold	147,293	–	–	1.86%	27
2019 Q2	$6.68M	Buy	147,293 +2,864	+2%	+$133K	1.56%	30
2019 Q1	$6.85M	Hold	144,429	–	–	1.69%	29
2018 Q4	$9.99M	Hold	144,429	–	–	2.18%	26
2018 Q3	$11.6M	Buy	144,429 +38,987	+37%	+$2.31M	2.35%	27
2018 Q2	$5.85M	Sell	105,442 -20,265	-16%	-$1.09M	1.99%	27
2018 Q1	$7.58M	Buy	+125,707	New	+$8.09M	2.35%	24

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dundas Partners's BMY Position: Q4 2021 in Review

Dundas Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2021, closing a stake of 180,191 shares — an estimated $10.7M sold.

Dundas Partners first reported a position in BMY in Q1 2018 and held it in 15 quarters. The position peaked at $12.1M in Q4 2020. 2,445 funds tracked by Wall St. Rank hold BMY as of Q4 2021.

Dundas Partners reported no remaining Bristol-Myers Squibb position as of Q4 2021 after selling out during the quarter.
Dundas Partners sold 180,191 Bristol-Myers Squibb shares in Q4 2021, an estimated $10.7M.
Dundas Partners first reported a position in Bristol-Myers Squibb in Q1 2018 and held it in 15 quarters.
Dundas Partners's Bristol-Myers Squibb position peaked at $12.1M in Q4 2020.
2,445 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2021.

Based on Dundas Partners's 13F filing for Q4 2021, filed 14 Feb 2022.